Overview

* Northwest Healthcare Q2 2025 revenue falls 16.9% to C$99 million due to asset sales

* Net income for Q2 2025 reaches C$32.6 mln, reversing prior year loss

* Co suspends DRIP and appoints CEO Zachary Vaughan to Board

Outlook

* Company manages rent deferral with Healthscope, expecting repayment by March 2026

Result Drivers

* ASSET SALES - Revenue decreased 16.9% in Q2 2025 due to non-core asset sales, partially offset by same property revenue growth

* SPNOI GROWTH - Same Property Net Operating Income increased by 2.8% driven by inflationary rent adjustments and improved recoveries

* DEBT REDUCTION - Proceeds from asset sales used to repay debt, reducing leverage to 48.5% from 50.0% at year-end 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net C$32.62

Income mln

Q2 FFO C$0.11

Per

Share

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the specialized reits peer group is "buy."

* Wall Street's median 12-month price target for Northwest Healthcare Properties REIT is C$5.55, about 14.2% above its August 11 closing price of C$4.76

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)